Clay Siegall and His Contributions towards Cancer Research

According to a research study, it has been shown that while cancer is caused by tobacco smoke or is inherited, there are times when cancer is unavoidable and is created naturally. The study conducted at the Johns Hopkins Kimmel Cancer Center suggests that most of the mutations leading to cancer occur naturally. According to the leading researchers of the project, Bert Vogelstein, and Cristian Tomasetti, the cells divide naturally, and many times they make some mistakes. While many of these mistakes happen in the unimportant part of the DNA, there are times when this error occurs in the cancer driver gene that can lead to cancer. If such gene gets mutated in the same cell more than a couple of times, it converts a healthy cell into cancer causing cell. While the researchers added that one could easily reduce the risk of cancer by eating healthy and maintaining their body, people cannot fully eliminate the chances of them having cancer since it happens naturally.

Clay Siegall is the CEO of Seattle Genetics and has been working towards a cure for cancer patients and to improve the lives of the cancer patients. He is also the co-founder of the company and has been working towards making the company one of the top one in cancer research since 1998. He has collaborated with many different laboratories worldwide to help them in cancer research. They aim to design therapies for cancer yo reduce the chances of relapse once the treatment is completed. The company has many different projects in the pipeline and is known for its innovative biotechnology products that are a blessing to the humans.

Clay Siegall has Ph.D. in Genetics from the famous George Washington University. He first joined Bristol-Myers Squibb of Pharmaceutical Research Institute as a senior research investigator. Due to his excellent work results, he was then promoted to the Principal scientist. But, this was not enough for him, and he wanted more from his career. He then joined the National Cancer Institute to become a staff fellow and Biotechnology fellow. It was then that he realized that he wanted to start his research and set up Seattle Genetics.